AL102-502
14 evidence topics · 3 sources
Objective
Effect of a single varegacestat dose on cardiac repolarization
Location and study date
Registry status, dates, and site
| Study characteristic | Quoted record |
|---|---|
| Protocol number | “AL102-502” |
| Sponsor | “Immunome, Inc.” |
| Overall status | “Completed” |
| Study start (actual) | “2025-02-24” |
| Primary completion (actual) | “2025-04-08” |
| Study completion (actual) | “2025-05-06” |
| First posted | “2025-03-03” |
| Last update posted | “2025-09-24” |
| Site | “Celerion”; “Tempe” |
Study design
Randomized, placebo- and moxifloxacin-controlled, three-way crossover
Registry design fields
| Study characteristic | Quoted record |
|---|---|
| Phase | “Phase 1” |
| Allocation | “Randomized” |
| Intervention model | “Crossover Assignment” |
| Masking | “This is a double-blind study (with respect to varegacestat and placebo only; moxifloxacin will be open label).” |
| Primary purpose | “Other” |
| Keyword | “thorough-QT” |
Eligibility criteria
Healthy adults aged 18 to 55 years
Exclusion criteria
Treatment
Single doses of varegacestat, placebo, and moxifloxacin 400 mg
Study outcomes
Rationale for using placebo-corrected QTc change as the primary endpoint
Primary endpoint: placebo-corrected QTc change and plasma concentrations
Delayed cardiac repolarization and torsade de pointes
Purpose of a thorough QT/QTc study and the threshold of regulatory concern
Positive control to establish assay sensitivity
Secondary endpoints: ECG parameters, pharmacokinetics, safety, and assay sensitivity
Statistical analysis description
Number of participants (Planned and analyzed)
Actual enrollment
| Study characteristic | Quoted record |
|---|---|
| Enrollment (actual) | “32” |
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
- AL102-502 is known only from its registry record. The record lists the study as “Completed”, with primary completion on 2025-04-08, and shows no posted results; no publication, congress presentation, or Immunome document reporting its results was identified, so the effect of varegacestat on the QTc interval is unknown from public sources.
- The study gave a single oral dose of varegacestat to 32 healthy participants aged 18 to 55 years, with women limited to those of non-childbearing potential. The registry record does not state the dose. In the phase 1 study of BMS-986115, the median accumulation ratio after once-daily dosing at 1.2 mg was 3.66, so exposure after a single dose is lower than exposure after 15 days of once-daily dosing.
- Moxifloxacin, the positive control, was given open label, and blinding applied to varegacestat and placebo only.